ArticlePhenomics (Cham, Switzerland)2023
International Nuclear Medicine Consensus on the Clinical Use of Amyloid Positron Emission Tomography in Alzheimer's Disease.
Article in Phenomics (Cham, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed.
- Diagnostic performance of an automated plasma p-tau217 chemiluminescent assay for detecting Aβ pathology in a Chinese memory clinic cohort.The journal of prevention of Alzheimer's disease · 2026Article
- The pathogenic role of gut microbiota dysbiosis in Alzheimer's disease: a narrative review of neuroimaging evidence.Journal of neural transmission (Vienna, Austria : 1996) · 2026Review
- Outer nuclear layer thinning as an in vivo biomarker for discriminating probable FTLD-tau from probable FTLD-TDP with PET-supported subtyping.Alzheimer's research & therapy · 2026Article
- Stratifying amyloid burden in early Alzheimer's disease using cascaded attention-guided vision transformer using [¹⁸F]Florbetapir PET.European radiology · 2026Article
- Plant-mediated green nanoparticles: combining nanometal and biometabolite potential for Alzheimer's treatment.Biomedical engineering online · 2026Review
- Amyloid-beta statuses prediction with free water MR imaging features in Alzheimer's disease using machine learning models.BMC medical imaging · 2026Article
- Potential diagnostic markers in Alzheimer's disease: current perspectives and future directions.Neurodegenerative disease management · 2026Review
- Effectiveness, safety, and biomarker dynamics of lecanemab in Chinese Alzheimer's disease population: a multicenter real-world study.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Plasma neurofilament light reflects more severe manifestation of Alzheimer's disease in men.Molecular psychiatry · 2025Article
- Discordant cerebrospinal fluid and positron emission tomography amyloid biomarkers in an APP mutation carrier presenting corticobasal syndrome.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Forebrain neural progenitors effectively integrate into host brain circuits and improve neural function after ischemic stroke.Nature communications · 2025Article
- Trajectory of changes in myelin basic protein levels in cerebrospinal fluid during ageing and its association with biomarkers of Alzheimer's disease.Translational psychiatry · 2025Article
- Molecular imaging: The bridge from human phenome to personalized precision medicine.European journal of nuclear medicine and molecular imaging · 2025Article
- Visual reading for [European journal of nuclear medicine and molecular imaging · 2025Article
- Predicting amyloid status in mild cognitive impairment: the role of semantic intrusions combined with plasma biomarkers.Frontiers in aging neuroscience · 2025Article
- Spatial-temporal dynamic evolution of lewy body dementia by metabolic PET imaging.European journal of nuclear medicine and molecular imaging · 2024Article
- PET imaging of synaptic vesicle glycoprotein 2 subtype A for neurological recovery in ischemic stroke.European journal of nuclear medicine and molecular imaging · 2024Article
- Impaired glymphatic function as a biomarker for subjective cognitive decline: An exploratory dual cohort study.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Screening of [ACS pharmacology & translational science · 2024Article
- Positron Emission Tomography Imaging of Synaptic Dysfunction in Parkinson's Disease.Neuroscience bulletin · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's disease (AD) is the main cause of dementia, with its diagnosis and management remaining challenging. Amyloid positron emission tomography (PET) has become increasingly important in medical practice for patients with AD. To integrate and update previous guidelines in the field, a task group of experts of several disciplines from multiple countries was assembled, and they revised and approved the content related to the application of amyloid PET in the medical settings of cognitively impaired individuals, focusing on clinical scenarios, patient preparation, administered activities, as well as image acquisition, processing, interpretation and reporting. In addition, expert opinions, practices, and protocols of prominent research institutions performing research on amyloid PET of dementia are integrated. With the increasing availability of amyloid PET imaging, a complete and standard pipeline for the entire examination process is essential for clinical practice. This international consensus and practice guideline will help to promote proper clinical use of amyloid PET imaging in patients with AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.